[Intrapleural administration of CDDP against malignant pleural effusions in breast cancer].
Malignant pleural effusion in the patients with breast cancer commonly occurs, and is a life-threatening factor. The present paper shows the usefulness of intrapleural administration of CDDP in six cases. A decrease of pleural effusions was observed in all cases. Treatment was effective in two cases of CR and four cases of PR. A median survival from initiation of intrapleural therapy is 17 months (range 2-47 months). This procedure produced distinctly fewer side effects than intravenous administration. The results of this trials suggest that CDDP should be considered as an active agent in the treatment of malignant pleural effusion in the patients with breast cancer.
Kikuchi
K
K
Dept. of Surgery of Tokyo Denryoku Hospital.
Tsuyuki
A
A
Fujishiro
Y
Y
Utsumi
T
T
Fujisaki
M
M
Kurihara
E
E
Uematsu
M
M
D000368:Aged; D001943:Breast Neoplasms / Q000150:complications* / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage; D007262:Infusions, Intravenous; D015409:Mastectomy, Radical; D008787:Metoclopramide / Q000008:administration & dosage; D008875:Middle Aged; D010994:Pleura; D010996:Pleural Effusion / Q000188:drug therapy*; D014839:Vomiting / Q000517:prevention & control
D008787:Metoclopramide; D002945:Cisplatin; D006854:Hydrocortisone